Matches in Wikidata for { <http://www.wikidata.org/entity/Q93253144> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q93253144 description "article scientifique publié en 2020" @default.
- Q93253144 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q93253144 description "im April 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q93253144 description "scientific article published on 27 April 2020" @default.
- Q93253144 description "wetenschappelijk artikel" @default.
- Q93253144 description "наукова стаття, опублікована 27 квітня 2020" @default.
- Q93253144 name "Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program" @default.
- Q93253144 name "Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program" @default.
- Q93253144 type Item @default.
- Q93253144 label "Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program" @default.
- Q93253144 label "Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program" @default.
- Q93253144 prefLabel "Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program" @default.
- Q93253144 prefLabel "Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program" @default.
- Q93253144 P1433 Q93253144-13914908-4483-42DB-8F6D-4B4D3B702222 @default.
- Q93253144 P1476 Q93253144-0353DF1B-7EB7-4B93-8741-F069C96F7170 @default.
- Q93253144 P2093 Q93253144-322C0062-E922-4420-BB0F-D3A10144DDF9 @default.
- Q93253144 P2093 Q93253144-44CBB5AB-70A6-4808-A5A3-D81C4D4324F0 @default.
- Q93253144 P2093 Q93253144-710D1FF6-A4EF-47A2-8D03-225180B02FC4 @default.
- Q93253144 P2093 Q93253144-81144E57-6B75-4041-B9F4-F81C37001537 @default.
- Q93253144 P2093 Q93253144-D8EBEDE6-F41F-4594-9EF6-AC181462EBB8 @default.
- Q93253144 P2093 Q93253144-FC56A2FE-7F01-46FF-A63D-4DCEE86DE5AA @default.
- Q93253144 P2860 Q93253144-9496B8EF-87B6-40C4-B714-588112F94AAF @default.
- Q93253144 P31 Q93253144-B6486D85-3A43-42A6-BFE2-23B98C7AD6D6 @default.
- Q93253144 P356 Q93253144-100B0071-A4A9-4C0D-B59A-CE45FD5D31F3 @default.
- Q93253144 P577 Q93253144-2993F73F-7098-49C6-A1C5-56EA5070F08D @default.
- Q93253144 P698 Q93253144-98C5504F-EF8C-4B65-87B5-A3C91BB729A5 @default.
- Q93253144 P356 FON-2019-0849 @default.
- Q93253144 P698 32338548 @default.
- Q93253144 P1433 Q2781597 @default.
- Q93253144 P1476 "Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program" @default.
- Q93253144 P2093 "Huamao M Lin" @default.
- Q93253144 P2093 "Maximilian J Hochmair" @default.
- Q93253144 P2093 "Peijie Hou" @default.
- Q93253144 P2093 "Pia Baumann" @default.
- Q93253144 P2093 "Susan Allen" @default.
- Q93253144 P2093 "Xiaoyun Pan" @default.
- Q93253144 P2860 Q27851440 @default.
- Q93253144 P31 Q13442814 @default.
- Q93253144 P356 "10.2217/FON-2019-0849" @default.
- Q93253144 P577 "2020-04-27T00:00:00Z" @default.
- Q93253144 P698 "32338548" @default.